Xenon Pharmaceuticals (XENE) Common Equity (2013 - 2026)
Xenon Pharmaceuticals (XENE) posted quarterly Common Equity of $1.3 billion for Q1 2026, up 90.04% year-over-year from $704.0 million in Q1 2025, and up 129.96% quarter-over-quarter from $581.8 million in Q4 2025.
Xenon Pharmaceuticals (XENE) Common Equity (2013 - 2026) Analysis & Trends
Xenon Pharmaceuticals (XENE) has reported Common Equity for 14 consecutive years, with $1.3 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 90.04% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (up 90.04% YoY), while the FY2025 annual figure was $581.8 million, down 22.94% from the prior year.
- Common Equity climbed to $1.3 billion in Q1 2026 per XENE's latest filing, from $581.8 million in the prior quarter.
- Across five years, Common Equity topped out at $1.3 billion in Q1 2026 and bottomed at $541.9 million in Q1 2022.
- Historically, Common Equity has averaged $753.0 million across 5 years, with a median of $721.5 million in 2022.
- Annual changes were most pronounced in 2022 — Common Equity soared 205.78% — and 2025, when it declined 29.87%.
- Xenon Pharmaceuticals' Common Equity stood at $721.5 million in 2022, then increased by 28.61% to $927.9 million in 2023, then retreated by 18.65% to $754.9 million in 2024, then dropped by 22.94% to $581.8 million in 2025, then jumped by 129.96% to $1.3 billion in 2026.
- Business Quant data shows XENE's Common Equity at $1.3 billion in Q1 2026, $581.8 million in Q4 2025, and $559.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Xenon Pharmaceuticals | 6.03 Bn | 6.03 Bn | - | 1.24 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.24 Bn |
| Mar 31, 2026 | 1.34 Bn |
| Dec 31, 2025 | 581.76 Mn |
| Sep 30, 2025 | 559.51 Mn |
| Jun 30, 2025 | 633.98 Mn |
| Mar 31, 2025 | 703.96 Mn |
| Dec 31, 2024 | 754.90 Mn |
| Sep 30, 2024 | 797.81 Mn |
| Jun 30, 2024 | 844.05 Mn |
| Mar 31, 2024 | 887.70 Mn |
| Dec 31, 2023 | 927.92 Mn |
| Sep 30, 2023 | 636.59 Mn |
| Jun 30, 2023 | 646.46 Mn |
| Mar 31, 2023 | 686.94 Mn |
| Dec 31, 2022 | 721.50 Mn |
| Sep 30, 2022 | 753.12 Mn |
| Jun 30, 2022 | 785.79 Mn |
| Mar 31, 2022 | 541.85 Mn |
| Dec 31, 2021 | 550.03 Mn |
| Sep 30, 2021 | 248.94 Mn |